Editor's note

This article was originally published on 18 February 2013 as part of the VacZine Analytics ExpertREACT series. It is reproduced here for archival purposes. Market conditions, pipeline statuses and regulatory positions described reflect the state of knowledge at that date.

Industry overview

According to VacZine Analytics calculations, the top five vaccine players reported approximately $21.4 billion in combined vaccine revenues in 2012, compared to $20.8 billion in 2011 - a modest increase of around 3%. For the second consecutive year, VacZine Analytics characterises the industry as essentially flat and "waiting for its next burst of growth." Bexsero®'s EU approval in January 2013 is now a potential growth catalyst that could set the stage for a meaningful step change.

Top 5 FY2012 Sales
$21.4bn

Combined vaccine revenues for the top five vaccine players in 2012, a modest ~3% increase on 2011

GSK: Cervarix Japan drag, strong combination franchise

GSK Biologicals reported $5.2 billion in 2012 - a 2% decline on 2011. Cervarix fell 46% to £270 million following Japan's HPV vaccination catch-up programme completion. Infanrix/Pediarix, Rotarix and Synflorix all grew 17-21%. Quadrivalent Fluarix QIV (newly approved December 2012) was positioned for significant 2013-14 season revenues. Nimenrix® (MenACWY), newly approved June 2012, recorded only £1 million in EU sales.

Sanofi: meningococcal ACW-Y franchise +94%

Sanofi Pasteur recorded €3,897 million in 2012, up 5.7% at constant exchange rates. Menactra (MenACWY) grew 94.6% in Q4 driven by Chile and Saudi Arabia national programme purchases, and 21.8% for the full year at €564 million. The company's dengue programme continued despite efficacy against only three of four serotypes in early Phase III data.

Merck: Gardasil +35%, Zostavax nearly doubles

Merck & Co had an impressive year. Gardasil grew 35% to $1.6 billion, boosted by the male indication in the US, emerging markets and Japan. Zostavax sales almost doubled to $651 million following improved supply and the launch of the UK shingles programme for over 70s.

Pfizer: Prevnar stable, pipeline builds

Pfizer's PCV-7/PCV-13 franchise registered $4,267 million - slightly above 2011. Under the motto "a Platform for all Ages and Geographies," Pfizer highlighted its pipeline in Staphylococcus aureus, nicotine, Clostridium difficile and IgE vaccines alongside its MenB programme.

"Bexsero®'s EU approval signals the potential end of Novartis Vaccines' loss-making period - and represents the industry's most significant new product in the meningococcal space since MenC."